Clinical Trials on Metastatic Bladder Cancer in Belgium

Total 1919 results

Jules Bordet Institute

Completed

Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers (MOMENTUM1)

Metastatic Colorectal Cancers | Metastatic Gastric Cancers | Metastatic Oesophageal Cancers | Metastatic Pancreatic Cancers | Metastatic Biliary Cancers | Metastatic Breast Cancers

Belgium
Cancer Research Antwerp

Completed

A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates (Destroy)

Metastatic Cancer

Belgium
Jules Bordet Institute
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)

Non-metastatic Muscle Invasive Bladder Cancer

France, Belgium
Cristal Therapeutics

Completed

A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NAPOLY)

Cancer | Metastatic Cancer | Solid Tumors

Netherlands, Belgium
Brugmann University Hospital

Unknown

Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers

Metastatic Breastcancer

Belgium
Novartis Pharmaceuticals

Terminated

An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404

Metastatic Cancer With Impaired Renal Function | Metastatic Cancer With Normal Renal Function

Belgium
Cliniques universitaires Saint-Luc- Université...

Unknown

An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors (NICE-COMBO)

Metastatic Cancer

Belgium
Xenothera SAS

Recruiting

FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23)

Metastatic Cancer | Advanced Solid Tumor

France, Belgium
University Hospital, Ghent

Completed

Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy

Surgery | Bladder Cancer | Urologic Cancer

Belgium
University Hospital, Ghent
Takeda

Completed

Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.

Prostate or Bladder Cancer

Belgium
Akamis Bio

Completed

Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)

Metastatic Colorectal Cancer | Metastatic Bladder Cancer | Solid Tumours of Epithelial Origin

Belgium, Spain
The Belgian Society of Medical Oncology

Recruiting

The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment

Metastatic Cancer

Belgium
University Hospital, Ghent

Completed

External Beam Radiotherapy for Muscle Invasive Bladder Cancer

Toxicity

Belgium
University Hospital, Ghent

Completed

Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

Metastatic Urothelial Cancer

Belgium
The Belgian Society of Medical Oncology
Illumina, Inc.; OncoDNA; PierianDx

Recruiting

A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre (BALLETT)

Solid Tumor | Metastatic Cancer

Belgium
The Belgian Society of Medical Oncology
Roche Pharma AG; Foundation Medicine; Sciensano

Recruiting

A Study to Examine the Value of Broad Agnostic Next Generation Sequencing (NGS) Panel Testing Versus Reimbursed Organ-directed NGS: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Center

Metastatic Cancer | Local Tumor Invasion

Belgium
KU Leuven
Agentschap voor Innovatie door Wetenschap en Technologie

Completed

Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer (SELEBLAT)

Bladder Cancer

Belgium
University Hospital, Ghent

Active, not recruiting

Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer

Toxicity

Belgium
Daiichi Sankyo
AstraZeneca

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Metastatic Cancer | Advanced Cancer

Spain, Korea, Republic of, Belgium, Italy, France, United States, Australia, Japan, Taiwan, United Kingdom
Association Pour La Recherche des Thérapeutiques...
Roche Pharma AG

Completed

Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma (CVH-CT02)

Recurrent Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder

France, Belgium
European Organisation for Research and Treatment...

Terminated

Adjuvant Radiation Therapy in Treating Patients With Brain Metastases

Metastatic Cancer

France, Finland, United Kingdom, Belgium, Israel, Germany, Switzerland, Netherlands, Turkey, Italy, Portugal, Spain, Latvia
Jessa Hospital

Completed

Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) (Prophylaxis001)

Bladder Cancer | Antibiotic-associated Diarrhea | Antibiotic Resistant Infection | Antibiotic Resistant Strain | Antibiotic Toxicity | Prostate Hyperplasia | Urosepsis

Belgium
GlaxoSmithKline

Completed

Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer

Neoplasms, Urinary Bladder

Belgium
Universitaire Ziekenhuizen KU Leuven

Recruiting

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer (SPARKLE)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis | Oligometastatic Disease | Hormone Sensitive Prostate Cancer

Belgium
Jules Bordet Institute
GlaxoSmithKline; Schering-Plough

Completed

Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer (LAPTEM)

Metastatic Breast Cancer | Brain Metastases | HER2 Positive

Belgium
Universiteit Antwerpen

Unknown

Sacral Neuromodulation and Pudendal Somatic Afferents

Overactive Bladder, Non Obstructive Urinary Retention

Belgium
University Hospital, Ghent
Astellas Pharma Inc; Medtronic

Completed

Treatment of the Overactive Bladder Syndrome: A Delphi Study

Overactive Bladder Syndrome

Belgium
University Hospital, Ghent

Terminated

TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) (TaPaS)

Overactive Bladder Syndrome

Belgium
Hyperfusion
University Hospital, Ghent

Unknown

DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria

Metastatic Lung Cancer | Cancer, Lung | Metastatic Liver Cancer | Cancer Liver | Perfusion Computed Tomography Target Lesion

Belgium
Jules Bordet Institute

Unknown

Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer

Breast Cancer | Metastatic Cancer

Belgium
University Hospital, Ghent
Kom Op Tegen Kanker

Recruiting

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle Invasive Bladder Cancer (EFFORT-MIBC)

Muscle-Invasive Bladder Carcinoma

Belgium
European Organisation for Research and Treatment...

Terminated

Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, Italy, Turkey, Slovakia
Amal Therapeutics
Boehringer Ingelheim

Active, not recruiting

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01)

Metastatic Colorectal Cancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | MSS

United States, Belgium, Switzerland, Germany
University Ghent
University Hospital, Geneva

Active, not recruiting

PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Metastatic | Oligometastatic Cancer

Norway, Spain, Belgium, Switzerland, Australia, Italy
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Metastatic Breast Cancer | Metastatic Triple Negative Breast Cancer

Japan, Belgium, France, Netherlands
Jules Bordet Institute

Completed

The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (PRECISION-F)

Metastatic Melanoma | Colorectal Cancer Metastatic | Metastatic Non-Small Cell Lung Carcinoma

Belgium
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
University Hospital, Ghent
Medtronic

Completed

OptiLUTS Part C: The Development of a Symptom Assessment Tool in Sacral Neuromodulation. (OptiLUTS)

Urinary Retention | Fecal Incontinence | Overactive Bladder Syndrome | Dysfunctional Voiding | Fowler Syndrome

Belgium
Vitadx
FONDATION FORCE POUR L'INNOVATION ET LA RECHERCHE EN SANTE

Recruiting

Demonstration of the Medical Interest of the VisioCyt® Artificial Intelligence Test (DMIA)

Non-muscle Invasive Bladder Cancer (NMIBC)

France, Belgium, Spain
Universiteit Antwerpen
Leiden University Medical Center

Unknown

Standardization of Lead Placement for Sacral Neuromodulation. Part 1

Overactive Bladder | Non Obstructive Urinary Retention

Belgium
Universiteit Antwerpen

Unknown

Sacral Neuromodulation & Urodynamics

Overactive Bladder | Non-obstructive Urinary Retention

Belgium
ABSCINT NV/SA

Not yet recruiting

HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 (HERMIA)

Metastatic Breast Cancer

Belgium
PharmaMar

Completed

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

Metastatic Colorectal Cancer | Pancreatic Cancer | Metastatic Breast Cancer

Spain, Belgium
Universiteit Antwerpen
Leiden University Medical Center

Unknown

Standardization of Lead Placement for Sacral Neuromodulation Part 2

Overactive Bladder | Non Obstructive Urinary Retention

Belgium
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Melanoma | Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Renal Cancer | Other Solid Cancers

United States, Belgium, Sweden, Germany, Canada, Spain, United Kingdom, Netherlands
Ipsen

Terminated

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Gastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic Tumours

United States, France, Belgium, Switzerland, Netherlands
European Organisation for Research and Treatment...

Completed

BCG With or Without Mitomycin in Treating Patients With Bladder Cancer

Bladder Cancer

Netherlands, Belgium, United Kingdom, Italy, Portugal, Turkey
Stemline Therapeutics, Inc.

Completed

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Metastatic Breast Cancer

Netherlands, Belgium
University Hospital, Ghent

Recruiting

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer (DART)

Prostate Cancer | Metastatic Cancer | Prostate Cancer Recurrent | Prostate Cancer Metastatic | Oligometastasis

Belgium
Amphora Medical, Inc.

Terminated

Cystoscopic Ablation Via RF Energy Clinical Trial (CARETI)

Overactive Bladder

Canada, Belgium

Clinical Trials on Metastatic Bladder Cancer in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations